The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index; 93 of the 168 sources its claims cite were checked for support.
Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease
Open accessAbstract
Different types of engineered nanoparticles have been demonstrated to be able to penetrate this barrier and serve as efficient drug delivery systems into the brain, making them a promising solution for future therapeutic development.
Overview
CoChat Summary
## TL;DR
This is a narrative review of nanoparticle-based strategies to move drugs across the blood–brain barrier for Alzheimer’s disease, with emphasis on surface functionalization, focused ultrasound, stimuli-responsive systems, exosomes, gene therapy, and magnetic nanoparticles. It concludes that these approaches are promising in preclinical studies but have not yet achieved clinical translation for AD.
## Key findings
- The review states that the blood–brain barrier is the main obstacle to AD drug delivery, and that engineered nanoparticles can improve targeting, loading capacity, bioavailability, and reduce systemic adverse effects.
- It identifies several strategies to enhance brain delivery: surface-functionalized nanoparticles, focused ultrasound (FUS) combined with microbubbles, stimuli-responsive nanoparticles, gene-therapy nanoparticles, exosome-mediated delivery, and magnetic nanoparticles.
- For physicochemical design, it reports that nanoparticles for brain delivery are generally considered suitable in the 100–200 nm range; very small particles (<30 nm) may be renally cleared, while larger ones (150–300 nm) may accumulate in liver and spleen.
- The paper notes that despite multiple encouraging preclinical examples, clinical application in trials is “nonexistent” for these advanced nanoparticle strategies in AD, and that only one brain-targeted nanoparticle therapy is approved overall (NanoTherm®, for brain cancer), not AD.
## Methods
- This is a review article, not an original experimental study.
- The authors report a comprehensive literature search using PubMed and Google Scholar, with keywords including nanoparticles, Alzheimer’s disease, in vitro studies, in vivo studies, encapsulated drug, surface functionalization, stimuli-responsive, focused ultrasound, and magnetic nanoparticles.
- They selected articles published preferably after 2020, requiring in vitro and/or in vivo studies, direct investigation of the BBB and/or AD, and positive or relevant experimental results.
## Limitations
- The paper states that many approaches remain limited by clinical translation barriers, including long-term safety, chronic toxicity, immunogenicity, quality control in large-scale production, regulatory hurdles, pricing, and off-target effects.
- It also states that animal models do not fully reproduce human AD, and that mice and rats “neither naturally nor experimentally induced develop AD” in the same way as humans; this limits translation to patients.
- Evident from the text: the article is a narrative review rather than a systematic review or meta-analysis, so the evidence synthesis is broader and less standardized than a formal systematic method.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Exosome’s structure. Adapted from [112,113]. This image was created with the software Canvas (https://www.canva.com/).](https://figures.cochat.ai/paper-figures/7438045ae5ad436aa1d8a167dd97995f/advances-in-strategies-to-transport-nanoparticles-across-the-bloodbrain-barrier-figure-4.jpg)
Verification
Claims the paper makes
87 Valid · 3 Not valid · 56 Not checked · 33 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“This protective barrier limits the entry of foreign substances, including drugs, into the central nervous system.”
- Also stated in: § 2. Challenges in Drug Delivery to the Brain · plain
“Although of the utmost importance for the existence of a stable and safe environment and the maintenance of its homeostasis, the BBB limits the action of drugs in the brain [6].”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > Abstract
What the sources say
- Supportedcites [6] Wu, 2023, The blood-brain barrier: Structure, regulation, and drug delivery, Signal Transduct. Target. Ther. source
The ‘Anatomical structure of the BBB’ section states that the barrier isolates foreign substances in the blood from the CNS and limits drugs entering the CNS. The Introduction likewise says an intact BBB impedes most blood-borne substances and excludes many drugs from the brain. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2. Challenges in Drug Delivery to the Brain · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Disrupting the BBB, which consists of opening the TJs of the brain using non-invasive physical methods like infusion of noxious agents (e.g., bradykinin that induces vasodilation) or injection of microbubbles (MBs) (small vehicles filled with gas), followed by sonication (e.g., focused ultrasound (FUS) sonication), is another strategy [16].”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > 2. Challenges in Drug Delivery to the Brain > Transport Mechanisms Across the BBB
What the sources say
- Partly supportedcites [16] Pardridge, W.M. (2022). A Historical Review of Brain Drug Delivery. Pharmaceutics, 14. sourceExperimental — accuracy not yet measured
The Introduction describes BBB disruption by intra-arterial infusion of noxious agents or intravenous microbubble injection followed by brain sonication. Sections 4.2 and 4.3 support tight-junction opening with focused ultrasound and microbubbles. But §4.3 describes these approaches as requiring operating-room treatment, not as non-invasive; §4.1 discusses bradykinin and its analogue as biochemical agents rather than non-invasive physical methods. Page numbers were not provided. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The main challenges related to intranasal administration lie in the transition from in vitro and animal models to humans due to the anatomical differences in the nasal cavity [15].”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > 2. Challenges in Drug Delivery to the Brain > Transport Mechanisms Across the BBB
What the sources say
- Supportedcites [15] Koo, 2024, Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations, Int. J. Nanomed. source
The “Differences Between in-vivo and in-vitro Models” section identifies anatomical differences between humans and animals as a challenge to extrapolating results from preclinical intranasal models to humans. It explicitly describes a translational gap, matching the cited claim. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This barrier is responsible for the regulation of molecule influx and efflux into and out of the brain.”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > 2. Challenges in Drug Delivery to the Brain
What the sources say
- Supportedcites [6] Wu, 2023, The blood-brain barrier: Structure, regulation, and drug delivery, Signal Transduct. Target. Ther. source
The Introduction says the BBB controls the entrance and expulsion of molecules between the vascular compartment and the brain. The “Physiology of the BBB” section also describes its regulation of molecular exchange between blood and brain tissue. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, prolonged BBB disruption associated with long-term treatment raises safety concerns, as it may facilitate neurotoxic effects in the brain [14].”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > 2. Challenges in Drug Delivery to the Brain > Transport Mechanisms Across the BBB
What the sources say
- Partly supportedcites [14] Poudel, P., and Park, S. (2022). Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems. Pharmaceutics, 14. sourceExperimental — accuracy not yet measured
Section 5.3 (page unavailable) raises uncertainty about the safety of repetitive and prolonged BBB opening, supporting the concern about long-term disruption. The available passage ends before naming a possible effect; Section 8 discusses nanoparticle-induced neurotoxicity but does not establish that prolonged BBB opening facilitates it. (LLM, conf=0.76)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
60 more claims · 28 with their cited sources checked
Create a free account to see all 179 claims and to verify the 23 references still open.
- Probably not a substantial claim. 45
- It may state two separate claims as one. 88
Citations
Cites
Shape effects of filaments versus spherical particles in flow and drug delivery
Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., & Discher, D. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.70 · Cited by 2,565 · cited 1×
“Consequently, by tailoring NPs’ shape, researchers can enhance transcytosis across the BBB, making shape another crucial parameter to consider during NPs design and production [32,35].”
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · cited 5×
“Their membrane is negatively charged and allows the passage of small lipophilic molecules and specific substances via transporters present in their surface [6].”
InfluentialA blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853 · cited 3×
“Carrier-mediated transport (CMT) refers to the transport of a variety of molecules facilitated by membrane-bound proteins entitled solute carrier (SLC) transporters [5].”
InfluentialSaraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609 · cited 1×
“As a result, most of the NPs studied for brain delivery have between moderate ( − 1 mV to − 15 mV) and high ( − 15 mV to –45 mV) negative ZP [28].”
Nanoparticles as drug delivery systems
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70901-5 · Cited by 1,445 · cited 2×
“Therefore, they have proven to be highly relevant in the AD context as they provide a protective vehicle to carry and deliver therapeutic agents to the brain safely [8].”
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · cited 1×
“However, the heterogeneity of these hallmarks cannot be fully comprehended in the light of a single hypothesis [4].”
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900 · cited 1×
“Some of the most common NDs are Alzheimer’s Disease (AD), Parkinson’s disease, spinal system atrophy, Huntington’s disease, amyotrophic lateral sclerosis, motor neuron disease, and spinocerebellar ataxia [2].”
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738 · cited 1×
“These can include increased paracellular permeability by loss of TJs, degradation of ECs and pericytes, modification in thickness of the basement membrane, astrocyte degeneration, changes in the expression of transporters/receptors present in the BBB, and so forth [41].”
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719 · cited 1×
“…expression of specific genes by inserting a functional gene copy to be expressed (e.g., mRNA) and even amplify, surpress, or correct gene expression, consequently resulting in gain or loss of function (e.g., clustered regularly interspaced short palindromic repeats (CRISPR)/Cas systems) [98,99].”
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Palmerston Mendes, L., Pan, J., & Torchilin, V. (2017) · Molecules · doi:10.3390/molecules22091401 · Cited by 701 · cited 1×
“Therefore, incorporating genetic material into NPs presents an appealing approach to overcome these challenges, since they can protect nucleic acid molecules as well as transport them to the desired locations [87,100].”
Research works printed but not linked: 4
- Dotiwala, A.K., McCausland, C., and Samra, N.S. (2025, October 01). Anatomy, Head and Neck: Blood Brain Barrier, Available online: https://www.ncbi.nlm.nih.gov/books/NBK519556/.
- (2026, April 17). Polymer Nanoparticles—An Overview|ScienceDirect Topics. Available online: https://www.sciencedirect.com/topics/materials-science/polymer-nanoparticles.
- Zhang, 2024, Multifunctional mesoporous nanoselenium delivery of metformin breaks the vicious cycle of neuroinflammation and ROS, promotes microglia regulation and alleviates Alzheimer’s disease, Colloids Surf. B Biointerfaces, 245, 114300
- Mutluay, 2022, Donepezil-loaded PLGA-b-PEG Nanoparticles Enhance the Learning and Memory Function of Beta-Amyloid Rat Model of Alzheimer’s Disease, Arch. Neuropsychiatry, 59, 281
Cited by
Begum, M. Y., Rajkumar, M., Govindaraj, P., Prathap, N., Sudha, P. N., Hamod, M. A., Alotaibi, H., & Uvarajan, D. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02381-5 · Cited by 1
Targeting Autophagy in Alzheimer's Disease: Role of the AMPK/mTOR Pathway and Drug Repurposing
Dubey, A., Chaurasia, A., Ansari, Z. A., Kushwaha, S. K., Saraf, I., Kashaw, S. K., Swami, R., & Kushwah, V. (2026) · Drug Development Research · doi:10.1002/ddr.70344 · Cited by 1
Metadata
- Authors
- Silva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C.
- Affiliations
- Universidade do Porto (PT)
- Corresponding author
- Loureiro, Joana A.
- Pereira, Maria Carmo
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2026-04-27
- Volume
- 19
- Issue
- 5
- Pages
- 685
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC13209752
- OpenAlex
- W7160150054
- Cited by
- 2
- References
- 126
- Citations by year
- 2026: 2
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- FCT/MCTES (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020)
- Foundation for Science and Technology (M-ERA-NET3/0001/2021)
- Project Nano4Glio (958174)
- European Union (NORTE2030-FEDER-02696100)
- FCT (CEEC-IND/01741/2021)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Alzheimer's disease, blood-brain barrier, engineered nanoparticles, nanoparticle drug delivery, brain drug delivery, clinical translation barriers, neurodegenerative disease treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease. https://app.cochat.ai/papers/10.3390/ph19050685
- The paper
- Silva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C. (2026). Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease. Pharmaceuticals. https://doi.org/10.3390/ph19050685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.